OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCXFree Report) in a research note published on Thursday. The firm issued a sell rating on the stock.

Other research analysts have also issued research reports about the company. Needham & Company LLC reiterated a buy rating and issued a $4.25 target price on shares of OncoCyte in a research report on Thursday, May 16th. Stephens reiterated an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. Finally, Benchmark reiterated a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $4.06.

Get Our Latest Research Report on OncoCyte

OncoCyte Stock Performance

OCX stock opened at $2.65 on Thursday. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.86. The stock’s 50 day moving average is $2.79 and its two-hundred day moving average is $3.05.

Insider Activity at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Andrew Arno acquired 33,898 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the transaction, the director now directly owns 69,054 shares in the company, valued at $203,709.30. The disclosure for this purchase can be found here. Insiders purchased 2,457,288 shares of company stock worth $7,176,400 in the last 90 days. 1.94% of the stock is currently owned by company insiders.

About OncoCyte

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Further Reading

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.